| Quarter | Prior | Estimate | Actual | Surprise | |
|---|---|---|---|---|---|
| Q4 2019 Pre-Market | EPS: REV: | 0.48 1.653B | |||
| Q3 2019 Pre-Market | EPS: REV: | 0.45 1.602B | |||
| Q2 2019 Pre-Market | EPS: REV: | 0.44 1.647B | |||
| Q1 2019 Pre-Market | EPS: REV: | 0.38 1.553B | |||
| Q4 2018 Pre-Market | EPS: REV: | 0.36 1.608B | 0.48 1.64B | 0.48 1.653B | 0.79% |
| Q3 2018 Pre-Market | EPS: REV: | 0.35 1.554B | 0.45 1.64B | 0.45 1.602B | -2.32% |
| Q2 2018 Pre-Market | EPS: REV: | 0.34 1.64B | 0.42 1.6B | 0.44 1.647B | 4.76% 2.94% |
| Q1 2018 Pre-Market | EPS: REV: | 0.32 1.506B | 0.38 1.56B | 0.38 1.553B | -0.45% |
| Q4 2017 Pre-Market | EPS: REV: | 0.31 1.566B | 0.35 1.59B | 0.36 1.608B | 2.86% 1.13% |
| Q3 2017 Pre-Market | EPS: REV: | 0.3 1.337B | 0.35 1.56B | 0.35 1.554B | -0.38% |
Data powered by Benzinga Pro Calendars - Start your FREE TRIAL today!
News Coverage
- The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering
- 10 Stocks To Watch For March 21, 2019
- Earnings Scheduled For March 21, 2019
- 6 Stocks Moving In Wednesday's After-Hours Session
- BofA Downgrades Michaels, Morgan Stanley Stays Bullish After Q4 Print